Integrated biorefinery for GPC and biosurfactants from soybean wet gums
An integrated biorefinery converting soybean wet gums into two high-value products: L-α-glycerylphosphorylcholine (GPC) for cognitive health and biosurfactants for industrial applications. Supports dual-mode operation for simultaneous production or biosurfactant-only production to improve market alignment. Uses selective enzymatic hydrolysis and purification to obtain a phosphate-ester-rich stream for biosurfactant fermentation.
Overview
The integrated biorefinery offers a dual-product approach to processing soybean wet gums into:
- L-α-glycerylphosphorylcholine (GPC), positioned as a premium nutraceutical for cognitive health
- Biosurfactants such as sophorolipids and rhamnolipids for industrial applications
The system supports two operating modes: simultaneous production of GPC and biosurfactants, or exclusive biosurfactant production. This flexibility is intended to optimize market adaptability and risk mitigation.
Technical specifications
The process leverages the composition of soybean wet gums by using glycerophospholipids as direct precursors for GPC via selective enzymatic hydrolysis and purification. A phosphate ester-rich stream is generated and used as a nutrient source for fermenting biosurfactants with Starmerella bombicola.
The biorefinery can switch between “Max Value” and “Max Volume” modes to align with market demands. The proposed production capacity range is 7,000–14,000 MT/year.
Technology readiness level
The current development stage is Technology Readiness Level 2, with ongoing lab-scale validation of conversion pathways. Future phases include scaling to pilot production, refining process economics, and engaging market off-takers. The technology’s patentability and flexible implementation are described as supporting potential for commercialization.
About Consulting-ai
Consulting-ai operates as a consultancy providing customized artificial intelligence solutions designed to transform enterprise operations. The company claims to develop proprietary technology integrated with scientific databases—including TOXNET, PubChem, DrugBank, and MatWeb—to deliver specialized results. Their approach utilizes adaptive deep learning models with specific fine-tuning and federated learning techniques that employ homomorphic encryption to maintain data privacy and regulatory compliance, such as GDPR, HIPAA, and REACH.
These services are aimed at helping organizations across various industries reduce operational costs, optimize processes, and improve the precision of their workflows. By emphasizing the use of proprietary data and tailored implementations, the firm positions its offerings as distinct from generic commercial AI models, intending to provide scalable, high-performance solutions for complex, heterogeneous data environments.
delivered to your inbox.